C4 Therapeutics (CCCC) Cash from Operations (2019 - 2026)
C4 Therapeutics' quarterly Cash from Operations came in at 29944000.0 in Q1 2026, up 10.04% year-on-year from 27212527.71 in Q1 2025, and down 35.22% quarter-over-quarter from 22145000.0 in Q4 2025.
C4 Therapeutics has reported Cash from Operations for 8 years, with the latest figure at 29944000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 10.04% year-over-year to 29944000.0; the trailing twelve-month figure through Mar 2026 stood at 95353000.0 (down 18.71% YoY), and the FY2025 full-year result was 98694000.0, down 51.47% from the prior year.
- Cash from Operations for Q1 2026 stood at 29944000.0, down from 22145000.0 in the prior quarter.
- The five-year high for Cash from Operations was 4974000.0 in Q2 2024, with the low at 33285000.0 in Q1 2025.
- Average Cash from Operations over 5 years is 23916000.0, with a median of 24133000.0 recorded in 2024.
- Year-over-year, Cash from Operations soared 73.82% in 2024 and sank 142.4% in 2025.
- Tracing CCCC's Cash from Operations over 5 years: stood at 29128000.0 in 2022, then climbed by 17.57% to 24009000.0 in 2023, then climbed by 25.31% to 17932000.0 in 2024, then retreated by 23.49% to 22145000.0 in 2025, then slumped by 35.22% to 29944000.0 in 2026.
- The last three Cash from Operations figures came in at 29944000.0 (Q1 2026), 22145000.0 (Q4 2025), and 31207000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -29.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.94 Mn |
| Mar 31, 2026 | -29.94 Mn |
| Dec 31, 2025 | -22.15 Mn |
| Dec 31, 2025 | -22.15 Mn |
| Sep 30, 2025 | -31.21 Mn |
| Sep 30, 2025 | -31.21 Mn |
| Jun 30, 2025 | -12.06 Mn |
| Jun 30, 2025 | -12.06 Mn |
| Mar 31, 2025 | -33.29 Mn |
| Mar 31, 2025 | -33.29 Mn |
| Dec 31, 2024 | -17.93 Mn |
| Dec 31, 2024 | -17.93 Mn |
| Sep 30, 2024 | -24.13 Mn |
| Sep 30, 2024 | -24.13 Mn |
| Jun 30, 2024 | -4.97 Mn |
| Jun 30, 2024 | -4.97 Mn |
| Mar 31, 2024 | -18.12 Mn |
| Mar 31, 2024 | -18.12 Mn |
| Dec 31, 2023 | -24.01 Mn |
| Dec 31, 2023 | -24.01 Mn |
| Sep 30, 2023 | -30.71 Mn |
| Sep 30, 2023 | -30.71 Mn |
| Jun 30, 2023 | -19.00 Mn |
| Jun 30, 2023 | -19.00 Mn |
| Mar 31, 2023 | -33.13 Mn |
| Mar 31, 2023 | -33.13 Mn |
| Dec 31, 2022 | -29.13 Mn |
| Dec 31, 2022 | -29.13 Mn |
| Sep 30, 2022 | -28.02 Mn |
| Sep 30, 2022 | -28.02 Mn |
| Jun 30, 2022 | -22.20 Mn |
| Jun 30, 2022 | -22.20 Mn |
| Mar 31, 2022 | -26.60 Mn |
| Mar 31, 2022 | -26.60 Mn |
| Dec 31, 2021 | -25.67 Mn |
| Dec 31, 2021 | -25.67 Mn |
| Sep 30, 2021 | -18.36 Mn |
| Sep 30, 2021 | -18.36 Mn |
| Jun 30, 2021 | -18.00 Mn |
| Jun 30, 2021 | -18.00 Mn |
| Mar 31, 2021 | -24.93 Mn |
| Mar 31, 2021 | -24.93 Mn |
| Dec 31, 2020 | -21.59 Mn |
| Dec 31, 2020 | -21.59 Mn |
| Sep 30, 2020 | -14.40 Mn |
| Sep 30, 2020 | -14.40 Mn |
| Jun 30, 2020 | -14.59 Mn |
| Jun 30, 2020 | -14.59 Mn |
| Mar 31, 2020 | -16.67 Mn |
| Mar 31, 2020 | -16.67 Mn |
| Dec 31, 2019 | -10.30 Mn |
| Dec 31, 2019 | -10.30 Mn |